Naira Muradyan1, Baris Turkbey2, William Dahut3, Peter Choyke2
1iCAD, Inc., Nashua, NH, United States; 2Molecular Imaging Program, National Cancer Institute, Bethesda, MD, United States; 3Medical Oncology Branch, National Cancer Institute, Bethesda, MD, United States
The T1 relaxation rate changes of 22 patients with metastatic prostate cancer with antiangiogenic therapy are reported. The bone and lymph node lesions were monitored through 4 cycles of therapy. And the observed T1 changes suggest the need for accurate estimation of those if quantitative analyses incorporating T1 vales are to be used for therapy response monitoring.